ABBV vs BMY
ABBV and BMY side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABBVAbbVie Inc. | BMYBRISTOL-MYERS SQUIBB COMPANY |
|---|---|---|
| Market cap | $433.58B | $131.90B |
| P/E (TTM) | 69.3 | 14.2 |
| P/B | — | 5.91 |
| P/S | 7.1x | 2.7x |
| Dividend yield | 2.69% | 3.82% |
| Revenue | $61.16B(TTM) | $49.19B(TTM) |
| Revenue growth (YoY) | 8.6% | -0.2% |
| Net income | $6.31B(TTM) | $9.28B(TTM) |
| Earnings growth (YoY) | -1.2% | 178.8% |
| EPS, diluted | $3.54(TTM) | $4.54(TTM) |
| EBIT margin | 24.6% | 21.8% |
| ROE | — | 31.6% |
| ROIC | 18.6% | 14.0% |
| Piotroski F | — | 7/9 |
| 1y total return | +26.7% | +47.8% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: ABBV frente a BMY
| Métrica | ABBV | BMY |
|---|---|---|
| Valor final | $62.9K | $13.9K |
| Retorno total | +529.1% | +38.6% |
| CAGR | +19.5% | +3.2% |
| Volatilidad | 25.8% | 25.2% |
| Sharpe | 0.67 | 0.10 |
| Sortino | 0.93 | 0.13 |
| Caída máxima | -45.1% | -47.7% |
Basado en 2600 días de negociación comunes, 2016-04-06 → 2026-08-07 · tasa libre de riesgo 3.9% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)